EU regulators recommend approval of Merck's drug Welireg for certain patients with VHL disease or advanced kidney cancer.

Merck & Co – known as MSD outside of the US and Canada – has shared positive results from a late-stage trial of a Keytruda ...

Merck has become inexpensive again and combines a good growth outlook with a nice and growing dividend. Learn why MRK stock ...

(RTTNews) - Merck & Co Inc. (MRK), Monday said China's National Medical Products Administration (NMPA) has approved Keytruda in combination with chemo therapy as neoadjuvant treatment, then as ...

Shares of Merck & Co. Inc. MRK inched 0.74% higher to $102.00 Friday, on what proved to be an all-around mixed trading ...

We recently compiled a list of the 8 Best American Dividend Stocks To Buy Right Now. In this article, we are going to take a ...

Merck & Co. Inc. closed $33.63 below its 52-week high ($134.63), which the company achieved on June 25th.

We recently published a list of 11 Best Beginner Stocks To Invest In Now. In this article, we are going to take a look at ...

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.09% of ...

Merck & Co. has shown off data on its ROR1-directed antibody-drug conjugate, trumpeting a 100% complete response rate but ...

(RTTNews) - Drug major Merck & Co., Inc. (MRK) announced Friday that its WELIREG (belzutifan) has received positive opinion from the European Medicines Agency's Committee for Medicinal Products for ...